TEPROTUMUMAB

CHEBI:CHEBI_753801

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2274812
brand_name
TEPEZZA
brand_name_base
TEPEZZA
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
marketing_start_date
20200121
package_marketing_start_date
21-JAN-20
active_ingredient_strength
55.5 mg/mL
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
route
INTRAVENOUS
marketing_category
DRUG FOR FURTHER PROCESSING
labeler_name
AGC Biologics A/S
manufacturer_name
Horizon Therapeutics USA, Inc.
generic_name
teprotumumab
active_ingredient_name
TEPROTUMUMAB
product_ndc
75987-130
spl_id
055c9298-15f1-4ba2-861d-7cae69c49696
package_ndc
75987-130-15
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (75987-130-15) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
application_number
BLA761143
unii
Y64GQ0KC0A
spl_set_id
3e6c54a1-cefd-4a5b-a855-ab9f268b6cce
nui
N0000193927
pharm_class_epc
Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]
pharm_class
Insulin-like Growth Factor-1 Receptor Inhibitors [MoA]
pharm_class_moa
Insulin-like Growth Factor-1 Receptor Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class